Endo buys Par Pharma for $8B to expand generics

May 18, 2015 12:11 PM

61 0

Endo International (ENDP) said Monday it has agreed to pay $8.05 billion to private equity firm TPG to buy Par Pharmaceutical Holdings, a deal aimed at expanding its growing generics business.

The stock-and-cash deal, approved by the boards of both companies, will create one of "the top five" generics manufacturers in terms of U.S. sales, Endo said.

Also read: Buffett's Berkshire Hathaway will not increase its Oncor offer

Read more

To category page